Prescription drug · BLA
Veopoz (Pozelimab) NDC 61755-014
Pozelimab 200 mg/mL · Injection, Solution · Intravenous, Subcutaneous · Regeneron Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 61755-014-01 | 61755001401 | 1 VIAL, SINGLE-DOSE in 1 CARTON (61755-014-01) / 2 mL in 1 VIAL, SINGLE-DOSE (61755-014-00)Marketed from Aug 18, 2023 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Veopoz
- Generic name (nonproprietary)
- pozelimab
- Active ingredients
- Pozelimab — 200 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intravenous, Subcutaneous
- Labeler
- Regeneron Pharmaceuticals, Inc.NDC labeler code 61755
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761339
- Marketing start
- Listing expires
- Other FDA classes
- Complement Inhibitors (Mechanism)
- Identifiers
- Product ID 61755-014_a8be5cf0-49ba-4795-a2e5-7ea07f495958SPL ID a8be5cf0-49ba-4795-a2e5-7ea07f495958SPL set ID a8d6f10e-9430-450a-a3dd-b538f9b2a308RxCUI 2663945, 2663952UNII 0JJ21K6L2I
- Pharmacologic class
- Complement Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N461755001401followed by a unit qualifier and the quantityPackage 61755-0014-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. VEOPOZ is a complement inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 61755-014
- What is NDC 61755-014?
- 61755-014 is the product NDC for Veopoz (pozelimab), Pozelimab 200 mg/mL injection, solution, listed with the FDA by Regeneron Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Veopoz (Pozelimab).
- What is the active ingredient?
- Pozelimab.
- Who is the labeler?
- Regeneron Pharmaceuticals, Inc., NDC labeler code 61755. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Veopoz?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.